A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

NCT07108270 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Endometrial

Interventions

BIOLOGICAL: Dostarlimab
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

GlaxoSmithKline